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Abstract
Introduction: The glycation process is a non-enzymatic modification of proteins occurring due to the reactions of reductive carbohydrates. 
The glycated residues lose their biological functions, and their removal process is ineffective. They accumulate, and as a result they cause 
an immunological response. The aim of this study was a determination of the concentrations of advanced glycation end-products and 
antibodies against carboxymethyl lysine (anti-CML) and carboxyethyl lysine (anti-CEL) in the sera of Graves’ orbitopathy patients.
Material and methods: The study group were patients from the Division of Endocrinology of the Medical University of Silesia (n = 25) 
suffering from Graves’ orbitopathy. The concentration of AGE-peptides using flow spectrofluorimetry method, and anti-CML and anti-CEL 
IgG antibodies using immunoenzymatic technique (ELISA), were measured in patients sera before and after methylprednisolone treatment.
Results: In sera of the study group the concentrations of AGE-peptides and anti-CML were significantly lower before and after treatment 
in comparison to the control group (p < 0.05). Mean values of anti-CEL concentrations were comparable (at both phases of treatment) 
with the value observed in the control group. After treatment the concentrations of AGE-peptides and anti-CEL significantly decreased 
(p < 0.05); however, the concentration of anti-CML was also lower but the observed change was not significant (p > 0.05).
Conclusions: In the course of Graves’ orbitopathy the glycation process is disturbed. The treatment modifies significantly the process by 
lowering the concentration of advanced glycation end-products and suppressing the immune response to them. 
(Endokrynol Pol 2016; 67 (4): 383–389)
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Streszczenie
Wstęp: Glikacja jest nieenzymatyczną modyfikacją białek zachodzącą z udziałem cukrów redukujących. Produkty glikacji białek tracą 
swoje biologiczne funkcje, przez co ich usuwanie staje się nieefektywne. Kumulują się one, a jako neoepitopy wywołują odpowiedź 
immunologiczną. Celem pracy była ocena stężeń końcowych produktów zaawansowanej glikacji białek (AGE-peptydów) i przeciwciał 
przeciwko karboksymetylolizynie (anty-CML) i karboksyetylolizynie (anty-CEL) w surowicy chorych na orbitopatię Gravesa.
Materiał i metody: Badaną grupę stanowili pacjenci Kliniki Endokrynologii Śląskiego Uniwersytetu Medycznego (n = 25) cierpiący na 
orbitopatię Gravesa. W surowicy krwi żylnej oznaczono zawartość AGE-peptydów przy użyciu metody spektrofluorymetrii przepływowej 
oraz przeciwciał anty-CML i anty-CEL w klasie IgG przy użyciu techniki immunoenzymatycznej (ELISA), przed i po leczeniu preparatem 
metyloprednizolonu.
Janusz Strzelczyk M.D., Division of Endocrinology, Department of Pathophysiology and Endocrinology, Silesian Medical University, 
Katowice, Ceglana 35, Poland, phone/fax: 32 35 81 366, e-mail: januszstr@op.pl
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Wyniki: W próbkach surowicy grupy badanej wykazano istotne statystycznie niższe stężenia AGE-peptydów i anty-CML zarówno przed, 
jak i po leczeniu w porównaniu z grupą kontrolną (p < 0,05). Średnie stężenia anty-CEL były porównywalne (w obu etapach leczenia) do 
obserwowanych w grupie kontrolnej. Po zastosowanym leczeniu stężenie AGE-peptydów oraz anty-CEL uległo znaczącemu obniżeniu 
(p < 0,05); stężenie anty-CML również było niższe, lecz zaobserwowana różnica nie była znamienna statystycznie (p > 0,05).
Wnioski: W przebiegu orbitiopatii Gravesa procesy glikacji białek ulegają zaburzeniu. Na podstawie wyników wstępnych badań można 
stwierdzić, że leczenie istotnie modyfikuje ten proces, zmniejszając stężenie końcowych produktów zaawansowanej glikacji oraz hamując 
odpowiedź immunologiczną przeciwko nim. (Endokrynol Pol 2016; 67 (4): 383–389)
Słowa kluczowe: orbitopatia Gravesa; terapia metyloprednizolonem; anty-CEL, anty-CML
Introduction
Graves’s orbitopathy (GO) is the most severe complica-
tion of Graves-Basedow disease (GD), which has a sig-
nificant impact on the quality of the patient’s life [1]. In 
more than half of the patients symptoms subside spon-
taneously, but about 3–5% require aggressive treatment 
due to the severe course of GO [2]. The extrathyroidal 
symptoms of GD, like GO, are the most difficult issues 
in the course of this pathological state. Unfortunately, 
the available treatment is not always effective [3, 4].
Graves’s orbitopathy is a chronic, autoimmune 
inflammation of orbital tissues, including eye muscles 
and periocular connective tissue. The role of immune 
system activation in its pathogenesis is doubtless and 
has been well documented [5–7, 8]. Activated T lympho-
cytes release cytokines and stimulate orbital fibroblasts 
to proliferate and produce glycosaminoglycans [9]. 
Recently, scientists have focused on the role of oxidative 
stress in the development of autoimmune disorders of 
the thyroid gland. Wilson et al. [10] showed increased 
free radicals and reduced antioxidant activity in active 
GD, and they also proved that an anti-thyroid medica-
tion modifies oxidative stress. Akarsu et al. [11] proved 
that the concentrations of malondialdehyde (MDA) — 
a marker of lipoxidation — were significantly higher in 
GO groups than in patients without ophthalmopathy 
and healthy controls, and the levels of glutathione - an 
important antioxidative agent - were significantly lower 
in the GO groups. Thyroid hormones also influence 
the synthesis and degradation of proteins [12]. The 
modification of protein structure may contribute to 
numerous pathological processes and can play a direct 
role in tissue damage.
Many researchers report an important role of 
a non-enzymatic modification of proteins caused by 
glucose, known as glycation. During that process, ad-
vanced glycation end products (AGEs) are formed by 
a non-enzymatic binding of free reducing sugars and 
reactive carbonyls to proteins. This reaction is called 
browning reaction or Maillard reaction [13]. The chemi-
cal structure of AGEs differs depending on the kind of 
amino compounds and sugars engaged in the process. 
N-e–(carboxymethyl) lysine (CML) is the major known 
AGE produced by diverse reaction conditions [13, 14]. 
Other AGEs such as N-e-(carboxyethyl) lysine (CEL), 
lactate lysine, pyrraline, pentosidine, and imidazoles are 
also frequently found, but also there are many others 
with unidentified structure and origin. Neoepitopes 
formed in glycation processes are recognised as foreign 
proteins by the B- and T-cell immune response [15, 
16]. The process of AGE formation is intensified by hy-
perglycaemia or an oxidative stress [17]. The presence 
of AGEs is associated with a large number of various 
dysfunctions, including diabetes, atherosclerosis, renal 
failure, and neurodegenerative diseases [13, 17]. It is 
noteworthy that GD patients are more likely to suf-
fer from diabetes and diabetic complications [18]. In 
autoimmune diseases, the role of AGEs and antibod-
ies against them (anti-CML, anti-CEL) has also been 
investigated. In psoriasis, patients in an active phase 
of the disease have significantly higher concentrations 
of AGE-peptides, as well as anti-CML and anti-CEL 
antibodies, than healthy individuals [14]. In contrast, 
serum AGE concentrations in chronic spontaneous 
urticarial (CSU) patients were significantly lower as 
compared with the healthy subjects [19]. Plasma soluble 
receptor for advanced glycation end products (sRAGE) 
may serve as a potential biomarker for disease activity 
and a future therapeutic target in systemic lupus ery-
thematosus (SLE) [20].
There is no available data on the role of advanced 
protein glycation in the pathogenesis of GO. Studies 
on animals have shown that the levels of the glycation 
product N-e-fructose lysine (FL) and CML identified 
by GC/MS in liver proteins decreased significantly in 
hyperthyroid rats, proving that thyroid hormones influ-
ence this process [21]. Due to the increasing interest in 
the usage of various receptors for advanced glycation 
end products (RAGE) (especially those being expressed 
on the surface of monocytes) as potential therapeutic 
targets in the states of inflammation and autoimmunisa-
tion [20], like GO, it is essential to examine the process 
of glycation in that state. 
The aim of the study was an estimation of the 
concentration of the peptides containing glycated 
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residues (AGE-peptides) and IgG antibodies against 
carboxymethyl lysine (anti-CML) and carboxyethyl 
lysine (anti-CEL) in the sera of patients suffering from 
GO before and after the treatment, in comparison to 
the sera of healthy control.
Material and methods
The study included archival sera samples from 
25 patients suffering from Graves-Basedow orbitopathy, 
obtained in the SUM Endocrinology Clinic in Katowice. 
A study group consisted of 22 women and 3 men, 
(48.8 ± 8.8 years old), with mean BMI index 24.8 ± 4.4 kg/m2. 
Patients were described by clinical activity index of orbit-
opathy (CAS, Clinical Activity Score), and most patients 
(n = 9) were classified as CAS = 6, and in NO SPECS 
classification most patients (n = 16) were in class 4. 
None of the patients suffered from diabetes. The control 
group consisted of healthy men (n = 19) and women 
(n = 21) aged 38.6 ± 9.0 years. Blood samples were 
taken in fasting from elbow veins of the study group 
twice: before and three weeks after applying the pulses 
of methylprednisolone. The treatment scheme was: 
six infusions of 0.5 g of methylprednisolone every two 
days. Sera obtained by centrifugation were stored at 
–80°C until the tests were performed. The study proto-
col was accepted by the Local Bioethical Commission of 
Silesian Medical University in Katowice. All participants 
were informed and signed the participation agreement.
The concentrations of IgG antibodies against carbox-
ymethyllysine (anti-CML) and carboxyethyl lysine (an-
ti-CEL) were determined using ELISA technique. ELISA 
plates (Maxisorp, Nunc, Denmark) were coated with the 
antigen solution at 10 mg⁄L in carbonate buffer. Anti-
gens consisted of glyoxal derivative of human serum 
albumin (HSA-CML) and sodium pyruvate derivative 
of human serum albumin obtained in reducing condi-
tions (HAS-CEL) [16]. The tested sera were diluted 800x 
in PBSTG (phosphate buffered saline with 0.1% Tween 
20 and 0.1% gelatine) for IgGs titration and incubated 
in a plate at 37°C for 1.5 hours. IgG antibody class was 
detected using goat anti-human IgG conjugated with 
horseradish peroxidise (Sigma, USA). Incubation with 
conjugates was performed at 37°C for 1.5 hours. The 
reactions were developed using substrates containing 
O-phenylenediamine and H2O2 (for anti-CEL IgG) and 
tetramethylbenzidine (for anti-CML IgG). Absorbances 
were measured using a PowerWave XS Reader (BioTek, 
USA), and the results were calculated using KCJunior 
software (BioTek, USA). Calibrations were performed 
using pooled sera originating from approximately 100 
healthy blood donors. 100-times dilution was accepted 
as 800 arbitral units⁄mL (AU ⁄ mL) for IgG antibodies (cali-
brating curve consisted of six standards: 25–800 AU⁄mL). 
This method has been previously described in the 
literature [14].
Measurement of advanced glycation end products 
(AGE-peptides) in tested sera was performed using flow 
spectrofluorimetry according to the method described 
by Zilin et al. [22]. Conditions were adapted for high-
pressure liquid chromatography HPLC Ultimate 3000 
equipment (Dionex, USA) with fluorescent detector 
RF 2000 (Dionex, USA). The obtained results were pre-
sented using basic parameters of descriptive statistics, 
such as mean value and standard deviation. The normal 
distribution of data was measured using Shapiro-Wilk’s 
test. Wilcoxon’s pair test was used to compare depend-
ent data before and after the treatment. Independent 
data from the study group and the control group were 
compared using nonparametric Kołmogorow-Smirnow 
and U Mann-Whitney tests. p < 0.05 was considered sta-
tistically significant. Calculations were performed with 
STATISTICA 10.0 software (StatSoft, Cracow, Poland). 
Results
The results of the study are presented in Table I. Pa-
tients suffering from GO showed significantly lower 
concentrations of AGE-peptides and antibodies against 
CML in comparison with the control group (p < 0.05). 
The differences in levels of antibodies against CEL 
were not significant (p > 0.05). After the treatment, 
concentrations of AGE-peptides and antibodies against 
CEL decreased significantly (p < 0.05), but anti-CML 
antibody levels remained unchanged (p > 0.05). These 
changes are shown in Figure 1, 2, and 3. It is notewor-
thy that mean anti-CEL antibody concentrations after 
Table I. The concentrations of AGE-peptides, anti-CML IgG 
and anti-CEL IgG in patients with GO (before and after 
treatment) and in healthy controls
Tabela I. Stężenia AGE-peptydów, anty-CML IgG, anty-CEL 
IgG u pacjentów z orbitopatią Gravesa (przed i po leczeniu) 
oraz u zdrowej grupy kontrolnej
Patients with GO Healthy  
controlsBefore  
treatment
After  
treatment
AGE peptides  
[mg/L]
17.4 ± 8.6*# 12.5 ± 6.2* 28.5 ± 15.4
(5.6–40.5) (4.8–25.7) (12.7–67.8)
anti-CML IgG  
[AU/mL]
18.0 ± 30.1* 10.9 ± 10.1* 41.1 ± 31.3
(3.2–148.7) (2.1–47.1) (8.6–135.9)
anti-CEL IgG  
[AU/mL]
70.9 ± 71.2# 53.2 ± 46.7 36.6 ± 34.5
(8.1–242.3) (7.7–198.4) (8.7–145.1)
*p < 0.05 in GO patients vs. healthy control; #p < 0.05 in GO patients before 
treatment vs. after treatment
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the treatment still matched those of the control group 
(p > 0.05), and anti-CML antibody and AGE-peptide 
levels were still lower (p < 0.05). The study did not 
reveal any differences in AGE-peptide, anti-CEL, and 
anti-CML values before and after the treatment with 
regard to NO SPECS or CAS classification. Table II 
shows correlations between the obtained values. AGE 
peptides concentrations show no significant correlation 
with anti-CEL and anti-CML neither before nor after 
the treatment (p > 0.05). AGE-peptides and anti-CEL 
values after the treatment decreased evenly due to 
significantly strong (AGE before & AGE after) and very 
strong (anti-CEL before & anti-CEL after) correlations. 
Antibodies against specific fragments of AGE-peptides 
revealed a moderate correlation (p < 0.05), but only 
before the treatment. Furthermore, the concentrations 
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Figure 1. Concentrations of anti-CEL IgG antibodies in serum of individual patients
Rycina 1. Stężenie przeciwciał anty-CEL IgG w surowicy pacjentów
Figure 2. Concentrations of anti-CML IgG antibodies in serum of individual patients
Rycina 2. Stężenia przeciwciał anty-CML IgG w surowicy pacjentów
387
Endokrynologia Polska 2016; 67 (4)
PR
A
C
E 
O
RY
G
IN
A
LN
E
of AGE-peptides positively correlated with the age of 
the patients, both before (R = 0.517) and after (R = 0.481) 
the treatment.
Discussion
The process of protein glycation in the course of GO 
is certainly disturbed. AGE peptide concentrations in 
the sera of GO patients are decreased in comparison 
to healthy individuals. It can be explained that in au-
toimmune disorders, the elimination of AGE peptides 
occurs through endocytosis by macrophage’s scavenger 
receptors, but it still requires further cytological studies 
[23]. What is more, the anti-CML concentrations were 
also decreased in GO patients in comparison to healthy 
subjects. In many autoimmune diseases increased 
levels of cytokines, like IFN-g or TNF, might suppress 
the production and secretion of antibodies, which may 
impair the response to the AGE peptides [7]. Moreover, 
it is observed that the concentration of AGE peptides in 
serum is increasing with patient age. They might be cu-
mulating in an organism throughout the ageing process 
because AGE peptides are long lasting molecules [24]. 
The study showed no significant correlation of 
the measured parameters before and after the treat-
ment with the results of the NO SPECS and CAS 
classifications. These scales determine the severity of 
eye changes in Graves’ disease based on the results of 
ophthalmic examination [25, 26]. The lack of correlation 
between obtained results and severity of GO could be 
explained by the natural history of GO. The primary 
demonstration of Th1 cells and connected cytokines 
(IFN-g, TNFa, IL-1a) in the early stage of the disease 
indicates that cell-mediated immunity predominates in 
the initial phase of the disease [27]. In the subsequent 
phases of GO, immune response is predominantly 
demonstrated by Th2 cells and cytokines (IL-5, IL-4, 
IL-10, and IL-13), which stimulate B-cells to produce 
autoantibodies against TSH-receptor [27]. No links 
between severity of GO and studied proteins can be 
explained in another way. The treatment with glucocor-
ticoids affects the regression of ocular lesions, although 
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Table II. The correlations between studied values
Tabela II. Korelacje pomiędzy badanymi wartościami
R Spearman
AGE before & AGE after 0.745*
Anti-CEL before 0.069
Anti-CML before 0.222
AGE after & Anti CEL after –0.036
Anti-CML after –0.076
Anti-CEL before & Anti-CEL after 0.958*
Anti-CML before 0.464*
Anti-CML before Anti-CML after 0.388
Anti-CEL after Anti-CML after 0.201
* p < 0.05 for statistically significant correlation
Figure 3. Concentrations of AGE-peptides in serum of individual patients
Rycina 3. Stężenia AGE-peptydów w surowicy pacjentów
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the effects of such treatment are visible only after about 
12 weeks [28]. Control examinations of studied patients 
were performed three weeks after the treatment, which 
could be an insufficient period of time to assess reliably 
the effectiveness of the glucocorticoid therapy.
In this study, the concentrations of AGE and anti-
CEL levels have been significantly decreased in GO 
patients after the methylprednisolone bolus. In contrast 
to our data, in another study the methylprednisolone 
boluses increased glycaemia, so it should intensify the 
formation of AGEs in our patients [29]. This shows that 
the applied immunosuppressive treatment can affect 
the formation of glycated proteins or removal of studied 
proteins from the circulation. 
Another study showed that immunosuppressive 
treatment has an impact on oxidative stress marker 
levels, so AGE distribution could be disturbed in GO 
patients after steroid boluses [30]. A non-significant de-
crease in the concentrations of anti-CML may indicate 
the existence of additional processes, which regulate the 
production of these antibodies. The existence of another 
pathway that regulates the production of anti-CML can 
be confirmed by the fact that there was a significant 
correlation between the concentrations of anti-CEL 
and anti-CML in patients before the treatment with 
glucocorticoids. After the immunosuppressive therapy 
this correlation was no longer observed. Moreover, the 
lack of significant correlation between the concentration 
of AGE peptides and linked antibodies (anti-CEL, anti-
CML) shows that the immune response to AGE peptides 
in GO patients is not proportional to the concentrations 
of glycation products.
The pathogenesis of exophthalmos occurring in 
patients with Graves-Basedow is caused by three pro-
cesses: cell infiltration, oedema, and fibrosis. Decreased 
levels of AGEs and analysed antibodies indicate the 
body’s response to the immunosuppressive therapy. 
It would be necessary to study the role of receptors for 
AGEs in the course of GO, and investigate the possibility 
of using them as a therapeutic target in the treatment.
Conclusions
The study findings allow us to conclude that in the 
course of GO the glycation process of proteins is de-
creased or the products of the process are degraded 
and removed from the circulation. The use of an im-
munosuppressant modulates progression of the glyca-
tion and the intensity of the B-cell immune response 
against newly-formed neoepitopes. There have been 
no studies carried out before to investigate that phe-
nomenon, and this study can improve the knowledge 
about pathogenesis of GO. Clinicians should be aware 
that treatment of GO affects not only the disease itself 
but also other processes like protein glycation. Further 
investigation of the glycation process in the course of 
Graves’ orbitopathy is essential due to the lack of suf-
ficient information.
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